Handelsbanken Fonder AB Has $521,000 Position in Progyny, Inc. (NASDAQ:PGNY)

Handelsbanken Fonder AB lifted its holdings in Progyny, Inc. (NASDAQ:PGNY) by 40.0% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 14,000 shares of the company’s stock after buying an additional 4,000 shares during the period. Handelsbanken Fonder AB’s holdings in Progyny were worth $521,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also modified their holdings of PGNY. Gotham Asset Management LLC purchased a new position in Progyny during the 3rd quarter valued at about $1,116,000. International Assets Investment Management LLC boosted its stake in shares of Progyny by 9,381.3% during the 4th quarter. International Assets Investment Management LLC now owns 158,053 shares of the company’s stock valued at $5,876,411,000 after buying an additional 156,386 shares during the period. Louisiana State Employees Retirement System purchased a new position in shares of Progyny during the 4th quarter valued at $870,000. Invesco Ltd. increased its stake in shares of Progyny by 67.0% in the third quarter. Invesco Ltd. now owns 888,427 shares of the company’s stock worth $30,224,000 after acquiring an additional 356,529 shares during the last quarter. Finally, Northern Trust Corp boosted its position in Progyny by 1.3% during the third quarter. Northern Trust Corp now owns 1,166,806 shares of the company’s stock valued at $39,695,000 after purchasing an additional 15,208 shares during the last quarter. Hedge funds and other institutional investors own 94.93% of the company’s stock.

Insider Activity

In related news, CFO Mark S. Livingston sold 11,165 shares of the business’s stock in a transaction dated Monday, April 1st. The stock was sold at an average price of $37.62, for a total transaction of $420,027.30. Following the transaction, the chief financial officer now directly owns 50,119 shares in the company, valued at $1,885,476.78. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In other news, President Michael E. Sturmer sold 6,395 shares of Progyny stock in a transaction dated Monday, April 1st. The shares were sold at an average price of $37.60, for a total transaction of $240,452.00. Following the sale, the president now directly owns 384,553 shares in the company, valued at approximately $14,459,192.80. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CFO Mark S. Livingston sold 11,165 shares of the stock in a transaction dated Monday, April 1st. The stock was sold at an average price of $37.62, for a total transaction of $420,027.30. Following the completion of the transaction, the chief financial officer now directly owns 50,119 shares of the company’s stock, valued at approximately $1,885,476.78. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 120,515 shares of company stock valued at $4,570,131. Insiders own 12.30% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on PGNY shares. SVB Leerink initiated coverage on Progyny in a report on Monday, February 26th. They set an “outperform” rating and a $49.00 price target for the company. Truist Financial reissued a “buy” rating and issued a $46.00 target price on shares of Progyny in a research report on Wednesday, April 17th. Barclays assumed coverage on shares of Progyny in a report on Wednesday, January 3rd. They set an “overweight” rating and a $48.00 price target on the stock. Leerink Partnrs reissued an “outperform” rating on shares of Progyny in a research report on Monday, February 26th. Finally, KeyCorp decreased their price target on Progyny from $45.00 to $43.00 and set an “overweight” rating for the company in a research note on Wednesday, February 28th. Ten equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average price target of $48.30.

Progyny Stock Down 1.5 %

Shares of NASDAQ PGNY opened at $32.06 on Wednesday. Progyny, Inc. has a 12 month low of $29.44 and a 12 month high of $44.95. The company has a market cap of $3.08 billion, a P/E ratio of 51.71, a P/E/G ratio of 1.35 and a beta of 1.48. The business’s 50 day moving average is $35.68 and its two-hundred day moving average is $35.64.

Progyny (NASDAQ:PGNY) last announced its earnings results on Tuesday, February 27th. The company reported $0.13 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.09 by $0.04. Progyny had a net margin of 5.70% and a return on equity of 12.64%. The business had revenue of $269.94 million for the quarter, compared to analyst estimates of $274.08 million. During the same quarter in the previous year, the firm posted $0.03 earnings per share. Progyny’s revenue was up 26.0% compared to the same quarter last year. Sell-side analysts expect that Progyny, Inc. will post 0.7 earnings per share for the current fiscal year.

About Progyny

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.